Ergomed plc Roy Ovel appointed as Chief Commercial Officer
01 April 2019 - 5:01PM
RNS Non-Regulatory
TIDMERGO
Ergomed plc
01 April 2019
PRESS RELEASE
Roy Ovel appointed as Chief Commercial Officer
London, UK - 1 April 2019: Ergomed plc, (LSE: ERGO) ('Ergomed'
or the 'Company'), a company focused on providing specialised
services to the pharmaceutical industry, today announces the
appointment of Roy Ovel as Chief Commercial Officer with immediate
effect.
Roy brings to Ergomed over 30 years' experience in international
business development with a number of the leading global CROs. This
has included roles with larger CROs such as ICON, TFS and Worldwide
Clinical Trials as well as with local, specialist CROs. At TFS
International, Roy was responsible for global sales and marketing
for more than four years, including leadership of the global
marketing team.
Roy will join Ergomed's Executive team and will be responsible
for global sales and business development activities across the
Company's full services offering. This will include a focus on the
benefits to customers of bringing together Ergomed's expertise in
pharmacovigilance and orphan drug development.
Roy will report directly to Dr Miroslav Reljanović, Executive
Chairman of Ergomed.
Dr Miroslav Reljanović, Executive Chairman of Ergomed,
commented: "Roy brings a wealth of experience to Ergomed. He has a
proven track record in building commercial success through an
understanding of customer's needs and delivering growth. I am
confident that operating across the Ergomed business he will make a
significant contribution to the Company through the services we
provide our clients."
Roy Ovel, Chief Commercial Officer of Ergomed, said: "Ergomed's
20-year track record in full-service, tailored contract clinical
development and its strength in pharmacovigilance offer significant
benefits to clients across the pharmaceutical industry. I very much
look forward to building on the company's success and its position
as a leading global CRO."
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402
975
Miroslav Reljanović (Executive Chairman)
Stuart Jackson (Chief Financial Officer)
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Freddie Barnfield (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications - for Tel: +44 (0) 20 3709 5700
UK enquiries
Chris Gardner / Mary-Jane Elliott ergomed@consilium-comms.com
Matthew Neal / Olivia Manser
MC Services - for Continental European Tel: +49 211 5292 5222
enquiries
Anne Hennecke
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing,
profitable services offering encompasses a complete suite of
specialist pharmacovigilance solutions, integrated under the
PrimeVigilance brand, in addition to a full range of high quality
contract research and trial management services (CRO). Leveraging
its CRO expertise, Ergomed also has a drug development portfolio of
co-development partnerships and wholly-owned programmes. For
further information, visit: http://ergomedplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAZMGFFGMVGLZZ
(END) Dow Jones Newswires
April 01, 2019 02:01 ET (06:01 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024